产品名称	Leronlimab (anti-CCR5), CCR5 抗体
别名	乐利单抗 \| 莱龙利单抗（抗CCR5）
英文别名	Recombinant Leronlimab Antibody \| Leronlimab (anti-CCR5) \| PRO 140 \| Vyrologi \| Leronlimab \| AM4 7 antibody \| C C chemokine receptor type 5 antibody \| C C CKR 5 antibody \| C-C chemokine receptor type 5 antibody \| C-C CKR-5 antibody \| C-C motif chemokine r
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	CCR5/CD195
应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
种属反应性	人(Human),恒河猴(Rhesus monkey)
偶联	Unconjugated
作用类型	拮抗剂
作用机制	CCR5 抗体

产品属性

抗体类型	Primary antibody
克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG4SP
轻链亚型	kappa
SDS-PAGE	27.7 kDa (Light Chain) & 52.5 kDa (Heavy Chain), under reducing conditions; 169.8 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	674782-26-4
分子类型	抗体

图片

SEC: Leronlimab (anti-CCR5) (Ab169252)

Leronlimab (anti-CCR5) (Ab169252) - SEC
The purity of Leronlimab (anti-CCR5) (Ab169252) is more than 95% verified by HPLC.

关联靶点（人）

CCR5 Tclin CC 趋化因子受体 5 型(C-C chemokine receptor type 5) (0 活性数据)

点击查看靶蛋白信息： CCR5

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

CCR5 Tclin C-C chemokine receptor type 5 (5640 活性数据)

点击查看靶蛋白信息： CCR5

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

安全和危险性（GHS）

SDS英文版

质量标准

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到6个结果

批号(Lot Number)	证书类型	日期	货号
ZJ24F1012673	分析证书	24-10-23	Ab169252
ZJ24F1012674	分析证书	24-10-23	Ab169252
ZJ24F1012675	分析证书	24-10-23	Ab169252
ZJ24F0303660	分析证书	24-03-25	Ab169252
ZJ24F0303659	分析证书	24-03-25	Ab169252
ZJ24F0303658	分析证书	24-03-25	Ab169252

可替换产品

参考文献

1. Burger DR, Parker Y, Guinta K, Lindner D. (2018) PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry^null Mice.. Biol Blood Marrow Transplant, 24 (2): (260-266). [PMID:29128556]
2. Dhody K, Pourhassan N, Kazempour K, Green D, Badri S, Mekonnen H, Burger D, Maddon PJ. (2018) PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection.. HIV Clin Trials, 19 (3): (85-93). [PMID:29676212]
3. Jiao X, Nawab O, Patel T, Kossenkov AV, Halama N, Jaeger D, Pestell RG. (2019) Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology.. Cancer Res, 79 (19): (4801-4807). [PMID:31292161]
4. Miao M, De Clercq E, Li G. (2020) Clinical significance of chemokine receptor antagonists.. Expert Opin Drug Metab Toxicol, 16 (1): (11-30). [PMID:31903790]
5. Forbes IT, Cooper DG, Dodds EK, Hickey DM, Ife RJ, Meeson M, Stockley M, Berkhout TA, Gohil J, Groot PH, Moores K.. (2000) CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound.. Bioorg Med Chem Lett, 10 (16): (1803-1806). [PMID:10969972] [10.1016/s0960-894x(00)00347-4]
6. Naya A, Sagara Y, Ohwaki K, Saeki T, Ichikawa D, Iwasawa Y, Noguchi K, Ohtake N.. (2001) Design, synthesis, and discovery of a novel CCR1 antagonist.. J Med Chem, 44 (9): (1429-1435). [PMID:11311066] [10.1021/jm0004244]
7. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. (1996) Molecular cloning and functional expression of a new human CC-chemokine receptor gene.. Biochemistry, 35 (11): (3362-7). [PMID:8639485]
8. Combadiere C, Ahuja SK, Tiffany HL, Murphy PM. (1996) Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES.. J Leukoc Biol, 60 (1): (147-52). [PMID:8699119]
9. Raport CJ, Gosling J, Schweickart VL, Gray PW, Charo IF. (1996) Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha.. J Biol Chem, 271 (29): (17161-6). [PMID:8663314]
10. Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J, Cheshier RC, Murphy PM. (2006) CCR5 deficiency increases risk of symptomatic West Nile virus infection.. J Exp Med, 203 (1): (35-40). [PMID:16418398]
11. Blanpain C, Migeotte I, Lee B, Vakili J, Doranz BJ, Govaerts C, Vassart G, Doms RW, Parmentier M. (1999) CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist.. Blood, 94 (6): (1899-905). [PMID:10477718]
12. Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, Norman R, Takaoka Y, Ding J, Arnold GF, Arnold E, Mitsuya H. (2006) Structural and molecular interactions of CCR5 inhibitors with CCR5.. J Biol Chem, 281 (12688-12698). [PMID:16476734]
13. Palani A, Shapiro S, Clader JW, Greenlee WJ, Cox K, Strizki J, Endres M, Baroudy BM. (2001) Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection.. J Med Chem, 44 (21): (3339-42). [PMID:11585437]
14. Thoma G, Streiff MB, Kovarik J, Glickman F, Wagner T, Beerli C, Zerwes HG. (2008) Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.. J Med Chem, 51 (24): (7915-20). [PMID:19053768]
15. Carter PH, Liu RQ, Foster WR, Tamasi JA, Tebben AJ, Favata M, Staal A, Cvijic ME, French MH, Dell V et al.. (2007) Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe.. Proc Natl Acad Sci USA, 104 (16): (6846-51). [PMID:17428923]
16. Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, Li T, Ma L, Fenalti G, Li J et al.. (2013) Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.. Science, 341 (6152): (1387-90). [PMID:24030490]
17. Cumming JG, Tucker H, Oldfield J, Fielding C, Highton A, Faull A, Wild M, Brown D, Wells S, Shaw J. (2012) Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.. Bioorg Med Chem Lett, 22 (4): (1655-9). [PMID:22266038]
18. Smyth DJ, Plagnol V, Walker NM, Cooper JD, Downes K, Yang JH, Howson JM, Stevens H, McManus R, Wijmenga C et al.. (2008) Shared and distinct genetic variants in type 1 diabetes and celiac disease.. N Engl J Med, 359 (26): (2767-77). [PMID:19073967]
19. Santella 3rd JB, Gardner DS, Duncia JV, Wu H, Dhar M, Cavallaro C, Tebben AJ, Carter PH, Barrish JC, Yarde M et al.. (2014) Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis.. J Med Chem, 57 (18): (7550-64). [PMID:25101488]
20. Peng P, Chen H, Zhu Y, Wang Z, Li J, Luo RH, Wang J, Chen L, Yang LM, Jiang H et al.. (2018) Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.. J Med Chem, 61 (21): (9621-9636). [PMID:30234300]
21. Angst D, Gessier F, Janser P, Vulpetti A, Wälchli R, Beerli C, Littlewood-Evans A, Dawson J, Nuesslein-Hildesheim B, Wieczorek G et al.. (2020) Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.. J Med Chem, 63 (10): (5102-5118). [PMID:32083858]
22. Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S, Pozzi S, Breitkreutz I, Kiziltepe T, Yasui H et al.. (2007) MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.. Blood, 110 (10): (3744-52). [PMID:17715391]
23. Gebhard Thoma,François Nuninger,Marc Schaefer,Kayhan G Akyel,Rainer Albert,Christian Beerli,Christian Bruns,Eric Francotte,Marcel Luyten,Duncan MacKenzie,Lukas Oberer,Markus B Streiff,Trixie Wagner,Hansrudolf Walter,Gisbert Weckbecker,Hans-Guenter Zerwes. (2004-04-02) Orally bioavailable competitive CCR5 antagonists.. Journal of medicinal chemistry, 47 ((8)): (1939-1955). [PMID:15055994]
24. De Lucca GV, Kim UT, Vargo BJ, Duncia JV, Santella JB, Gardner DS, Zheng C, Liauw A, Wang Z, Emmett G, Wacker DA, Welch PK, Covington M, Stowell NC, Wadman EA, Das AM, Davies P, Yeleswaram S, Graden DM, Solomon KA, Newton RC, Trainor GL, Decicco CP, Ko SS.. (2005) Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.. J Med Chem, 48 (6): (2194-2211). [PMID:15771462] [10.1021/jm049530m]
25. Lagu B, Gerchak C, Pan M, Hou C, Singer M, Malaviya R, Matheis M, Olini G, Cavender D, Wachter M.. (2007) Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma.. Bioorg Med Chem Lett, 17 (15): (4382-4386). [PMID:17587570] [10.1016/j.bmcl.2007.01.115]
26. Jayasuriya H, Herath KB, Ondeyka JG, Polishook JD, Bills GF, Dombrowski AW, Springer MS, Siciliano S, Malkowitz L, Sanchez M, Guan Z, Tiwari S, Stevenson DW, Borris RP, Singh SB.. (2004) Isolation and structure of antagonists of chemokine receptor (CCR5).. J Nat Prod, 67 (6): (1036-1038). [PMID:15217290] [10.1021/np049974l]
27. Merritt JR, Liu J, Quadros E, Morris ML, Liu R, Zhang R, Jacob B, Postelnek J, Hicks CM, Chen W, Kimble EF, Rogers WL, O'Brien L, White N, Desai H, Bansal S, King G, Ohlmeyer MJ, Appell KC, Webb ML.. (2009) Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists.. J Med Chem, 52 (5): (1295-1301). [PMID:19183043] [10.1021/jm801416q]
28. Li B, Jones ED, Zhou E, Chen L, Baylis DC, Yu S, Wang M, He X, Coates JA, Rhodes DI, Pei G, Deadman JJ, Xie X, Ma D.. (2010) Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 2: Discovery of highly potent anti-HIV agents.. Bioorg Med Chem Lett, 20 (17): (5334-5336). [PMID:20674358] [10.1016/j.bmcl.2010.05.046]
29. Laborde E, Macsata RW, Meng F, Peterson BT, Robinson L, Schow SR, Simon RJ, Xu H, Baba K, Inagaki H, Ishiwata Y, Jomori T, Matsumoto Y, Miyachi A, Nakamura T, Okamoto M, Handel TM, Bernard CC.. (2011) Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.. J Med Chem, 54 (6): (1667-1681). [PMID:21341682] [10.1021/jm1012903]
30. Zhu A, Zhan W, Liang Z, Yoon Y, Yang H, Grossniklaus HE, Xu J, Rojas M, Lockwood M, Snyder JP, Liotta DC, Shim H.. (2010) Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity.. J Med Chem, 53 (24): (8556-8568). [PMID:21105715] [10.1021/jm100786g]
31. Haney KM, Zhang F, Arnatt CK, Yuan Y, Li G, Ware JL, Gewirtz DA, Zhang Y.. (2011) The natural product CCR5 antagonist anibamine and its analogs as anti-prostate cancer agents.. Bioorg Med Chem Lett, 21 (18): (5159-5163). [PMID:21820898] [10.1016/j.bmcl.2011.07.058]
32. Brocklehurst KJ, Broo A, Butlin RJ, Brown HS, Clarke DS, Davidsson Ö, Goldberg K, Groombridge SD, Kelly EE, Leach A, McKerrecher D, O'Donnell C, Poucher S, Schofield P, Scott JS, Teague J, Westgate L, Wood MJ.. (2011) Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.. Bioorg Med Chem Lett, 21 (24): (7310-7316). [PMID:22061639] [10.1016/j.bmcl.2011.10.033]
33. Zhang Y, Arnatt CK, Zhang F, Wang J, Haney KM, Fang X.. (2012) The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents.. Bioorg Med Chem Lett, 22 (15): (5093-5097). [PMID:22770928] [10.1016/j.bmcl.2012.05.127]
34. Zhang F, Arnatt CK, Haney KM, Fang HC, Bajacan JE, Richardson AC, Ware JL, Zhang Y.. (2012) Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.. Eur J Med Chem, 55 (395-408). [PMID:22901310] [10.1016/j.ejmech.2012.07.049]
35. Abdel-Magid AF.. (2013) Targeting CCR2 Receptor To Treat Inflammation Diseases and Disorders.. ACS Med Chem Lett, 4 (4): (371-372). [PMID:24900677] [10.1021/ml400055e]
36. Karlström S, Nordvall G, Sohn D, Hettman A, Turek D, Åhlin K, Kers A, Claesson M, Slivo C, Lo-Alfredsson Y, Petersson C, Bessidskaia G, Svensson PH, Rein T, Jerning E, Malmberg Å, Ahlgen C, Ray C, Vares L, Ivanov V, Johansson R.. (2013) Substituted 7-amino-5-thio-thiazolo[4,5-d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1).. J Med Chem, 56 (8): (3177-3190). [PMID:23516963] [10.1021/jm3012273]
37. Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Metz M, Harwig C, Li TS, Yang W, Bogucki D, Zhu Y, Langille J, Veale D, Ba T, Bey M, Baird I, Kaller A, Krumpak M, Leitch D, Satori M, Vocadlo K, Guay D, Nan S, Yee H, Crawford J, Chen G, Wilson T, Carpenter B, Gauthier D, Macfarland R, Mosi R, Bodart V, Wong R, Fricker S, Schols D.. (2013) Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.. J Med Chem, 56 (20): (8049-8065). [PMID:24090135] [10.1021/jm401101p]
38. Arnatt CK, Zaidi SA, Zhang Z, Li G, Richardson AC, Ware JL, Zhang Y.. (2013) Design, syntheses, and characterization of pharmacophore based chemokine receptor CCR5 antagonists as anti prostate cancer agents.. Eur J Med Chem, 69 (647-658). [PMID:24095757] [10.1016/j.ejmech.2013.09.004]
39. Asano S, Gavrilyuk J, Burton DR, Barbas CF.. (2014) Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc.. ACS Med Chem Lett, 5 (2): (133-137). [PMID:24563723] [10.1021/ml400370w]
40. Yuan Y, Arnatt CK, El-Hage N, Dever SM, Jacob JC, Selley DE, Hauser KF, Zhang Y.. (2013) A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional Activities.. Medchemcomm, 4 (5): (847-851). [PMID:23682308] [10.1039/c3md00080j]
41. Arnatt CK, Adams JL, Zhang Z, Haney KM, Li G, Zhang Y.. (2014) Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents.. Bioorg Med Chem Lett, 24 (10): (2319-2323). [PMID:24731275] [10.1016/j.bmcl.2014.03.073]
42. Xu GG, Zaidi SA, Zhang F, Singh S, Raborg TJ, Yuan Y, Zhang Y.. (2015) Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents.. Bioorg Med Chem Lett, 25 (17): (3721-3725). [PMID:26096680] [10.1016/j.bmcl.2015.06.029]
43. Akgün E, Javed MI, Lunzer MM, Powers MD, Sham YY, Watanabe Y, Portoghese PS.. (2015) Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).. J Med Chem, 58 (21): (8647-8657). [PMID:26451468] [10.1021/acs.jmedchem.5b01245]
44. Zhan P, Pannecouque C, De Clercq E, Liu X.. (2016) Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.. J Med Chem, 59 (7): (2849-2878). [PMID:26509831] [10.1021/acs.jmedchem.5b00497]
45. Wu CH, Song JS, Kuan HH, Wu SH, Chou MC, Jan JJ, Tsou LK, Ke YY, Chen CT, Yeh KC, Wang SY, Yeh TK, Tseng CT, Huang CL, Wu MH, Kuo PC, Lee CJ, Shia KS.. (2018) Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.. J Med Chem, 61 (3): (818-833). [PMID:29314840] [10.1021/acs.jmedchem.7b01322]
46. Qin LH, Wang ZL, Xie X, Long YQ.. (2018) Discovery and synthesis of 6,7,8,9-tetrahydro-5H-pyrido[4,3-c]azepin-5-one-based novel chemotype CCR2 antagonists via scaffold hopping strategy.. Bioorg Med Chem, 26 (12): (3559-3572). [PMID:29805075] [10.1016/j.bmc.2018.05.027]
47. Sun Y, Xu W, Fan N, Sun X, Ning X, Ma L, Liu J, Wang X.. (2017) Design, synthesis and biological evaluation of (E)-3,4-dihydroxystyryl 4-acylaminophenethyl sulfone, sulfoxide derivatives as dual inhibitors of HIV-1 CCR5 and integrase.. Bioorg Med Chem, 25 (3): (1076-1084). [PMID:28082070] [10.1016/j.bmc.2016.12.035]
48. Wang C,Zhang YF,Guo S,Zhao Q,Zeng Y,Xie Z,Xie X,Lu B,Hu Y. (2021) GPR52 Antagonist Reduces Huntingtin Levels and Ameliorates Huntington's Disease-Related Phenotypes.. J Med Chem, 64 (2.0): (941-957). [PMID:33185430] [10.1021/acs.jmedchem.0c01133]
49. Arnatt CK,Falls BA,Yuan Y,Raborg TJ,Masvekar RR,El-Hage N,Selley DE,Nicola AV,Knapp PE,Hauser KF,Zhang Y. (2016) Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.. Bioorg Med Chem, 24 (22.0): (5969-5987). [PMID:27720326] [10.1016/j.bmc.2016.09.059]
50. Deng, H H and 14 more authors.. (1996) Identification of a major co-receptor for primary isolates of HIV-1.. Nature, (20): [PMID:8649511]
51. Dragic, T T and 10 more authors.. (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.. Nature, (20): [PMID:8649512]
52. Samson, M M and 21 more authors.. (1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.. Nature, (22): [PMID:8751444]
53. Liu, R R and 9 more authors.. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.. Cell, (9): [PMID:8756719]
54. Ansari-Lari, M A MA, Liu, X M XM, Metzker, M L ML, Rut, A R AR and Gibbs, R A RA.. (1997) The extent of genetic variation in the CCR5 gene.. Nature genetics, [PMID:9207783]
55. Kuhmann, S E SE, Platt, E J EJ, Kozak, S L SL and Kabat, D D.. (1997) Polymorphisms in the CCR5 genes of African green monkeys and mice implicate specific amino acids in infections by simian and human immunodeficiency viruses.. Journal of virology, [PMID:9343222]
56. Zhang, L L and 7 more authors.. (1997) HIV type 1 subtypes, coreceptor usage, and CCR5 polymorphism.. AIDS research and human retroviruses, (1): [PMID:9359654]
57. Mummidi, S S, Ahuja, S S SS, McDaniel, B L BL and Ahuja, S K SK.. (1997) The human CC chemokine receptor 5 (CCR5) gene. Multiple transcripts with 5'-end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory regions and noncoding exons.. The Journal of biological chemistry, (5): [PMID:9388201]
58. Carrington, M M and 5 more authors.. (1997) Novel alleles of the chemokine-receptor gene CCR5.. American journal of human genetics, [PMID:9399903]
59. Rizzuto, C D CD and 6 more authors.. (1998) A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.. Science (New York, N.Y.), (19): [PMID:9632396]
60. Oppermann, M M, Mack, M M, Proudfoot, A E AE and Olbrich, H H.. (1999) Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus.. The Journal of biological chemistry, (26): [PMID:10085131]
61. Farzan, M M and 8 more authors.. (1999) Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry.. Cell, (5): [PMID:10089882]
62. Blanpain, C C and 10 more authors.. (1999) Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity.. The Journal of biological chemistry, (2): [PMID:10383387]
63. Magierowska, M M and 12 more authors.. (1999) Novel variant of the CCR5 gene in a Vietnamese population.. Microbes and infection, [PMID:10917742]
64. Tamasauskas, D D, Powell, V V, Saksela, K K and Yazdanbakhsh, K K.. (2001) A homologous naturally occurring mutation in Duffy and CCR5 leading to reduced receptor expression.. Blood, (1): [PMID:11369664]
65. Kraft, K K and 5 more authors.. (2001) Characterization of sequence determinants within the carboxyl-terminal domain of chemokine receptor CCR5 that regulate signaling and receptor internalization.. The Journal of biological chemistry, (14): [PMID:11448957]
66. Bannert, N N and 6 more authors.. (2001) Sialylated O-glycans and sulfated tyrosines in the NH2-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines.. The Journal of experimental medicine, (3): [PMID:11733580]
67. and Paterlini, M Germana MG.. (2002) Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity.. Biophysical journal, [PMID:12496074]
68. Liu, Shuqun S, Fan, Shixiu S and Sun, Zhirong Z.. (2003) Structural and functional characterization of the human CCR5 receptor in complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular modeling studies.. Journal of molecular modeling, [PMID:14517611]
69. Schweneker, Marc M, Bachmann, André S AS and Moelling, Karin K.. (2005) JM4 is a four-transmembrane protein binding to the CCR5 receptor.. FEBS letters, (14): [PMID:15757671]
70. Hüttenrauch, Friederike F, Pollok-Kopp, Beatrix B and Oppermann, Martin M.. (2005) G protein-coupled receptor kinases promote phosphorylation and beta-arrestin-mediated internalization of CCR5 homo- and hetero-oligomers.. The Journal of biological chemistry, (11): [PMID:16144840]
71. Muzny, Donna M DM and 113 more authors.. (2006) The DNA sequence, annotation and analysis of human chromosome 3.. Nature, (27): [PMID:16641997]
72. Sáez-Cirión, Asier A and 7 more authors.. (2006) Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks.. Retrovirology, (8): [PMID:17092330]
73. Wilkin, Timothy J TJ and 12 more authors.. (2007) HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, (15): [PMID:17243065]
74. Agrawal-Gamse, Caroline C and 9 more authors.. (2009) Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.. Journal of virology, [PMID:19692476]
75. Schnur, Einat and 12 more authors.. (2011) The conformation and orientation of a 27-residue CCR5 peptide in a ternary complex with HIV-1 gp120 and a CD4-mimic peptide.. Journal of molecular biology, (29): [PMID:21763489]
76. Tadagaki, Kenjiro K and 7 more authors.. (2012) Human cytomegalovirus-encoded UL33 and UL78 heteromerize with host CCR5 and CXCR4 impairing their HIV coreceptor activity.. Blood, (24): [PMID:22496149]
77. Sauvageau, Etienne E and 7 more authors.. (2014) CNIH4 interacts with newly synthesized GPCR and controls their export from the endoplasmic reticulum.. Traffic (Copenhagen, Denmark), [PMID:24405750]
78. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ.. (2002) TTD: Therapeutic Target Database.. Nucleic acids research, (1): [PMID:11752352]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Leronlimab (anti-CCR5), CCR5 抗体

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器